Biodexa Pharmaceuticals annual operating margin
2015
2016
2017
2018
2019
2020
2021
2022
2023
Biodexa Pharmaceuticals Operating Margin Growth & History (BDRX)
Biodexa Pharmaceuticals's operating margin was −2,103.41% for fiscal 2023.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −2,103.41% | −825.59 pp |
| 2022 | 2022-12-31 | −1,277.83% | −67.10 pp |
| 2021 | 2021-12-31 | −1,210.73% | +5506.47 pp |
| 2020 | 2020-12-31 | −6,717.20% | −5037.97 pp |
| 2019 | 2019-12-31 | −1,679.23% | −1069.58 pp |
| 2018 | 2018-12-31 | −609.65% | +732.72 pp |
| 2017 | 2017-12-31 | −1,342.37% | −612.81 pp |
| 2016 | 2016-12-31 | −729.55% | +209.94 pp |
| 2015 | 2015-12-31 | −939.49% | — |
Biodexa Pharmaceuticals operating margin trends
Over the last five fiscal years, Biodexa Pharmaceuticals's operating margin decreased from −609.65% to −2,103.41%, a change of −1493.76 percentage points.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...
